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Biogerontology is sometimes viewed as similar to other forms of biomedical research in that it seeks
to understand and treat a pathological process. Yet the prospect of treating ageing is extraordinary in
terms of the profound changes to the human condition that would result. Recent advances in bio-
gerontology allow a clearer view of the ethical issues and dilemmas that confront humanity with
respect to treating ageing. For example, they imply that organismal senescence is a disease process
with a broad spectrum of pathological consequences in late life (causing or exascerbating cardiovas-
cular disease, cancer, neurodegenerative disease and many others). Moreover, in laboratory animals,
it is possible to decelerate ageing, extend healthy adulthood and reduce the age-incidence of a broad
spectrum of ageing-related diseases. This is accompanied by an overall extension of lifespan,
sometimes of a large magnitude. Discussions of the ethics of treating ageing sometimes involve
hand-wringing about detrimental consequences (e.g. to society) of marked life extension which,
arguably, would be a form of enhancement technology. Yet given the great improvements in
health that decelerated ageing could provide, it would seem that the only possible ethical course
is to pursue it energetically. Thus, decelerated ageing has an element of tragic inevitability: its
beneﬁts to health compel us to pursue it, despite the transformation of human society, and even
human nature, that this could entail.
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1. WHAT IS BIOGERONTOLOGY FOR?
The last decade has seen many remarkable develop-
ments in the biology of ageing, some of them
described by other contributors to this special issue.
These advances engender not only a sense of excite-
ment and optimism but also, at times, a degree of
unease and uncertainty. Questions and comments
from members of the public and from journalists pre-
sent at the recent Royal Society Discussion Meeting on
‘The new science of ageing’ (10–11th May 2010)
suggested that some present were wondering, ner-
vously: ‘What do these scientists actually hope to
achieve?’ In this essay, I will discuss the goals of bio-
gerontology (the study of the biology of ageing), and
their ethical implications.
Much research on the biology of ageing is directed
towards one of two goals. The ﬁrst is intellectual,
and one of the greatest remaining challenges to
science: an understanding of the ageing process. It is
a strange feature of the ﬁeld of biogerontology that,
despite all the recent advances, the fundamental mech-
anisms of ageing remain uncertain. A dominant idea
within the ﬁeld is that stochastic accumulation of
damage to biomolecules is a major driver of ageing,
while processes that reduce levels of such damage
promote longevity [1]. Yet, this notion has yet to
ascend from the status of hypothesis to that of
proven fact. The sense of moving at high speed
towards the solution of a great mystery makes bio-
gerontology a wonderful ﬁeld to be working in at
the moment.
The second goal of research on ageing is to improve
the health of older people. Here, biogerontology is
akin to other biomedical research topics, sharing
with them the goal of understanding the biological
mechanisms that underlie pathology. The particular
value of such understanding is that it enables the
development of therapeutic treatments, leading to
improved health and wellbeing. For example, the
identiﬁcation of bacteria as pathogens eventually
leads to the development of antibiotics. But if bioger-
ontology is just another area of biomedical research,
does this mean that ageing is a disease, to be treated
as if it were the common cold? Should we be seeking
a cure for ageing?
2. IS AGEING A DISEASE?
If something is a disease then one should try to cure it.
However, the question of what is a disease and what is
not can be a slippery one, and sensitive to cultural
perspective. For example, during much of the last
century, gay people were viewed as mentally ill. Our
view of ageing-related illness is also subject to such
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late-onset Alzheimer’s disease (occurring after age
65) was deﬁned as a pathology, as opposed to the natu-
ral senility accompanying the second childhood of
advanced old age. Is the logical endpoint of this pro-
cess of redeﬁning isolated components of the ageing
process as pathology to view the entire ageing process
as pathological?
Whether ageing should be viewed as a disease or a
non-pathological process accompanying disease has
been debated since classical times [2]. Yet from the
perspective of modern biogerontology, there is little
to distinguish biological ageing from a disease state
[3]. Ageing is a process characterized by a broad spec-
trum of pathologies the sum of which leads inevitably
to death [4], and its biology by loss of homeostasis
and accumulation of molecular damage [1]. But is
this sufﬁcient grounds to consider it a disease?
Human health has been deﬁned in terms not only of
absence of disease, but also in terms of the presence of
a level of function that is typical of human beings of a
given age and gender [5]. By this view, ageing is a
normal process and therefore distinct from disease.
Thus, although ageing is characterized by a broad
spectrum of diseases, at the same time it is a normal
process, and therefore not pathological.
Arguably, this apparent paradox may be resolved by
reference to the evolutionary theory of ageing, which
provides a biological perspective upon the function
and signiﬁcance of the ageing process [3]. According
to the evolutionary theory, ageing is a consequence
of a reduction in the force of selection against
mutations with deleterious effects later in life [6,7].
This leads to accumulation within populations of
alleles with deleterious effects later in life—particularly
alleles that also have beneﬁcial effects on reproductive
ﬁtness early in life [8]. The evolutionary theory pro-
vides the bleak insight that ageing serves no purpose
in terms of ﬁtness, but instead is a lethal genetic dis-
ease that afﬂicts all human beings. Arguably, the
signiﬁcance of the universality of ageing is not that
ageing is not a disease, but rather that it is a special
form of disease. To argue that ageing is not a disease
by virtue of its universality is as misleading as it is to
argue that the Basenji is not a dog because it does
not bark.
The clinical redeﬁnition of ageing as a disease state
would not only make sense, but it would also foster the
development of therapies of beneﬁt to older people.
For example, it would provide incentive to drug com-
panies to proﬁt by developing effective anti-ageing
therapies. It would also help to deter those marketing
bogus treatments for ageing, and protect older people
from being swindled [9,10]. In the USA, for example,
the Federal Drug Administration (FDA) is responsible
for ensuring the safety and efﬁcacy of medical products
at the federal level. Because ageing is not viewed as a
disease, orally administered drugs directed against
ageing fall under FDA regulations for cosmetic medi-
cine and are, therefore, not subject to same the
rigorous testing requirements as other drugs that
reduce disease [9,11]. Redeﬁnition of ageing as a dis-
ease would lead to proper safety and efﬁcacy testing of
anti-ageing treatments.
3. HOW TO TREAT AGEING
Recent advances in research on ageing have suggested
a number of different approaches that could improve
late-life health and wellbeing. Yet, there is no clear
consensus on the ideal form that treatments for
ageing should take.
(a) What form should treatments
for ageing take?
In terms of treatments for ageing, three different goals
of biogerontology may be distinguished, which have
been denoted compressed morbidity, arrested ageing
and decelerated ageing [11]. With compressed morbid-
ity, the aim is to identify treatments that protect
against late-life illnesses without tampering with the
underlying ageing process. This would produce
improvements in health among the elderly without
any major extension of lifespan, and a reduction of
the period of disability experienced by elderly people
in their ﬁnal years. This would be beneﬁcial both in
terms of improved wellbeing, and lowered healthcare
costs. Although wholesome, these aspirations are
somewhat unrealistic. For example, they only make
sense if ageing and age-related disease are clearly dis-
tinguishable, but this is not the case: they are to a
high degree part and parcel. Consistent with this,
interventions in ageing in laboratory animals have
achieved slowed ageing and delayed age-related illness,
but not compressed morbidity without life extension.
However, the goal of compressed morbidity may, to
some degree, be achieved by reducing risk factors for
late-life diseases that are distinct from ageing, such
as obesity and inactivity.
Arrested ageing involves stopping ageing entirely, or
even reversing it, as would be achieved by taking a dip
in the mythical fountain of youth. Perhaps, these pos-
sibilities will one day be realized, along with others
such as interstellar travel, the creation of artiﬁcial con-
sciousness and reanimation after cryonic suspension.
Yet based on the current state of play in biogerontology,
arrested ageing remains a very remote possibility, and is
therefore not a topic of any pressing concern.
Unlike the other two goals, decelerated ageing is
less an aspiration for what research on ageing should
seek to achieve as a view on what it probably can
achieve. Work on animal models has shown us that a
variety of interventions can slow ageing and, impor-
tantly, delay the onset of diseases of ageing [12].
This has important implications in terms of possible
future strategies for reducing levels of late-life disease.
(b) A silver bullet for diseases of ageing?
Much of the serious illness in the developed world is
the result of diseases for which ageing is a major risk
factor. These include many forms of cancer, cardiovas-
cular disease, neurodegenerative diseases such as
Alzheimer’s and Parkinson’s disease, macular degener-
ation, arthritis and many, many others. Treating
diseases of ageing individually are subject to a law of
diminishing returns because of the rapid increase
with age in the risk of a broad spectrum of diseases.
It is for this reason that successful treatment of indi-
vidual diseases of ageing yields relatively small
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challenge of treating illnesses in the elderly must at
times seem like Heracles’ trials of combating the
multi-headed Hydra. Each time one head was severed,
two more would sprout in its place. Likewise, a patient
might survive a serious cardiac episode with the help of
antihypertensive drugs only to succumb to cancer and
dementia. Arguably, current research on diseases of
ageing fails the Hydra test insofar as it investigates
them individually, piecemeal. Researchers studying
cancer, cardiovascular disease and neurodegenerative
diseases tend to work in separate research institutes,
publish in different journals, go to different research
conferences and develop treatments that are selectively
effective against their target disease.
In principle, a more effective way to tackle human
age-related illness would be to intervene in ageing
itself [14,15]. Deceleration of ageing, demonstrated in
animal models, potentially applicable in humans, pro-
vides protection against the full spectrum of diseases
of ageing thereby assuring late-life health (ﬁgure 1),
and strikes at the heart of the Hydra of ageing.
4. A CLOSER LOOK AT DECELERATED AGEING
Current research on the biology of ageing suggests that
there is a reasonable possibility that treatments that
decelerate human ageing could be developed, given
the will to do so. It is therefore worth considering
the implications of decelerated ageing more closely.
Clearly, deceleration of ageing could bring great
beneﬁts in terms of improved health. But one
common concern about treatments for ageing is that
they might extend the moribund stage at the end of
life. Hospitals might become choked with chronically
ill, elderly patients, languishing for years bedbound
and miserable, at enormous cost to taxpayers.
Animal model studies show that decelerated ageing
extends the healthy period of adulthood. However, it
could well extend the years of disability too, and
result in an expansion of morbidity—at least in absol-
ute terms (i.e. years of life), though perhaps not in
relative terms (percentage of life). In this respect,
decelerated ageing could prove to be a mixed blessing.
Decelerated ageing also has other ethically sensitive
implications.
(a) Decelerated ageing and lifetime
risk of disease
A question I am sometimes asked about the effects of
decelerated ageing on laboratory animals is: what do
they die of? The answer is ageing-related diseases—
more speciﬁcally, a spectrum of diseases that may or
may not differ from those that afﬂict control, shorter-
lived animals. Thus, decelerated ageing is not expected
to change the overall, lifetime risk of disease; rather, it
reduces disease incidence at any given age. This is well
illustrated by the effects of dietary restriction on
rodents [16]. Figure 2 depicts schematically the effects
of a treatment that decelerates ageing, which extends
lifespan and reduces the frequency of ageing-related
diseases (e.g. cancer) at any given age, for example
age A. However, at age B, where the treated group
has reached a state of ageing equivalent to that of the
control group at age A, a similar incidence of cancer
would be expected. Overall, the lifetime probability
of developing ageing-related diseases would be
expected to change little.
If lifetime risk of a given disease is unchanged, this
might not, at ﬁrst glance, appear to represent a real
improvement in health. However, I believe that such
a conclusion would be erroneous, as the following
argument illustrates. Consider a disease that is not
ageing related: smallpox, caused by the Variola virus.
The full eradication of this terrible disease in 1977
was one of the greatest achievements of biomedical
research. However, one consequence of smallpox era-
dication was to increase the frequency of late onset
Alzheimer’s disease (deﬁned as a disease that same
year). This it must have done, since it increased the
number of individuals surviving to a ripe old age, at
which this condition is more frequent.
This illustrates a broader principle: that reduction
of one mortal risk often increases exposure to others.
The introduction of iron helmets during the First
World War led to an increase in the frequency of
patients with head injuries by reducing the number
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Figure 1. (a) A piecemeal approach to study diseases of
ageing generates treatments that are limited in scope, and
which lead to the rapid replacement of one disease by
another (e.g. cardiac ischaemia by Alzheimer’s disease).
(b) A more rational approach to reduce a broad spectrum
of age-related diseases would be to treat the underlying
cause of all these pathologies: the underlying ageing process.
Note that this dichotomous scheme is polemical in character.
In fact, recent biomedical studies are increasingly identifying
interconnections between late-life pathologies. For example,
type 2 diabetes is linked to risk of dementia, driven by
vascular disease.
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(%) alive
A B
Figure 2. Decelerated ageing may not change lifetime risk
of disease. Risk of, say, cancer is greatly reduced at age A
in the treated population. However, risk of cancer may well
be the same at age A (grey line, untreated) and age B
(black line, treated).
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successful control of any given disease is to substitute
it for a range of later life pathologies. Since we all die,
there is no such thing as lifetime protection against
pathology, only deferral of pathology. This deferral
is precisely what decelerated ageing would achieve.
The only differenceisthatinsteadof substitutingsmall-
pox now with Alzheimer’s later in life it would (in all
likelihood) substitute Alzheimer’s now for Alzheimer’s
later. Like curing smallpox now, the latter would be as
great an achievement as curing Alzheimer’s now.
Yet a lingering doubt remains. Surely smallpox
taking the life of a child is more serious than an old
woman at the end of her life developing and eventually
dying from Alzheimer’s disease? Perhaps, but it is an
error of youth to think that with age comes a readiness
to accept the consequences of ageing, and to tolerate
its attendant illnesses. Tolerance of diseases of ageing
is grounded in the historically ancient attitude of con-
sidering ageing a necessary part of the cycle of life.
This tradition, called apologism by the historian
Gerald Gruman, is relatively strong in western culture
and is, to some extent, rooted in the stoic philosophy
of ancient Rome [17].
(b) The endpoint of decelerated ageing
The example of smallpox can be used to illustrate
another odd characteristic of decelerated ageing. One
can ask: what should the goals of smallpox research
be? Here, the answer is clear: the eradication of small-
pox. But consider the consequences of success with
respect todeceleratedageing, say using Richard Miller’s
tentative projection: greatly reduced rates of ageing-
related illness, an average lifespan of 112 years, and a
maximum lifespan of 140 [18]. Given that lifetime
risk of ageing-related illness would not be expected
to change, people would still die from diseases of
ageing in similar numbers, only later. Thus, the
moral imperative driving the research—to relieve suf-
fering from diseases of ageing—would not have been
fulﬁlled; the urgency of further research to decelerate
ageing still further would remain. It seems that we
would be morally obligated to continue on indeﬁnitely,
seeking ever greater decelerations of ageing, ever later
postponements of illness and greater extensions of life-
span. Unlike smallpox research, there is no endpoint.
This is rather unsettling, and evocative of philosopher
Leon Kass’s anxious characterization of biomedical
research as a ‘runaway train headed to a post-human
future’ [19]. Yet, in the end, the shape of the future
is so uncertain and subject to future discoveries
within the ﬁeld, and the potential beneﬁts so great,
that none of these arguments seem to come even
close to being reasons for stopping research that may
lead to deceleration of human ageing.
(c) The dilemma of decelerated ageing
Decelerating human ageing would have two outcomes
that are very different in ethical terms. Firstly, it would
greatly reduce the frequency of ageing-related illness at
any given age. This could achieve an amelioration of
human suffering on a very large scale, perhaps com-
parable in magnitude only to that resulting from the
development of antibiotics. This would be a triumph
of human endeavour.
Secondly, it would lead to extended lifespan—
perhaps, eventually, of a large magnitude. Of course,
life expectancy has increased greatly over the course
of the last century due to better sanitation and nutri-
tion, and advances in medicine and healthcare
provision. This is usually taken as an argument for
rather than against Civilization. Yet, the possibility of
very large increases in lifespan—let us say, for argu-
ment’s sake, to 150 years—is one that many ﬁnd
unnerving. Arguably, an intervention resulting in rad-
ical life extension would constitute an enhancement
technology, belonging in the same category of inter-
ventions as cosmetic surgery, cognitive enhancement
and perceptual enhancement [20]. Unlike medical
treatments, the perceived value of enhancement tech-
nologies is often highly sensitive to local differences
in cultural perspective, and can involve difﬁcult ques-
tions about human identity. Life extension of a large
magnitude has these qualities [21]. Thus, decelerated
ageing presents a dilemma. Either one must pursue it
and reduce suffering but risk extending lifespan to a
degree that is socially and existentially problematic;
or one must abjure it thereby avoiding the troubles
that life extension may cause, but permitting avoidable
suffering on a great scale.
Arguably, the only realistic course is the ﬁrst one. Of
these two outcomes of decelerated ageing, protection
against disease, and life extension, the ﬁrst carries far
greater moral weight. The possibility of alleviating suf-
fering on such a scale is one that we are morally
obligated to pursue, however ambivalent we may feel
about the second outcome. Some commentators,
including life cycle traditionalists, have argued that
ageing is a good thing, such that preventing it to any
degree would be wrong [22–24]. But given the
health beneﬁts of decelerated ageing, although we
may not particularly want life extension (though
many, of course, do), we may simply have to accept
it as a side effect of a greater beneﬁt. This is a curious
circumstance, comparable to imaginary scenarios
where a cure for Alzheimer’s disease also resulted in
cognitive enhancement to far beyond normal capa-
bility, or where a new treatment for cardiovascular
disease boosted libido to extravagant levels.
Tragic inevitability is part of the human condition
and, like theatrical tragedy, one that can possess a
strange beauty. The tragic feature of decelerated
ageing is the impossibility of separating the aspects of
treatment and enhancement. This characteristic effec-
tively compels us to embrace a posthuman future. The
only serious option is to adapt as best we can to a
future involving ever greater extension of lifespan.
With wise and adaptable government in the future, it
ought to be possible to achieve this. Yet in the end, the
challenge of adjusting to a world where we live much
longer, healthy lives is in some respects a delightful one.
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